Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

PHASE1TerminatedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

August 26, 2019

Primary Completion Date

June 26, 2024

Study Completion Date

June 26, 2024

Conditions
Lymphoma
Interventions
DRUG

HMPL-689

HMPL-689 is a PI3Kδ inhibitor

Trial Locations (27)

11590

Clinical Research Alliance, Inc, Westbury

28204

Levine Cancer Institute- Atrium Health, Charlotte

30322

Winship Cancer Institute of Emory University, Atlanta

33520

Tampereen yliopistollinen sairaala, Tampere

33604

CHU de Bordeaux - Hôpital Haut-Lévêque, Pessac

44000

CHU de Nantes - Hotel Dieu, Nantes

75246

Baylor Scott and White Research Institute, Dallas

77339

Renovatio Clinical, Houston

78229

University of Texas Health Science Center at San Antonio, San Antonio

92801

Innovative Clinical Research Institute, Anaheim

Pacific Cancer Medical Center, Anaheim

93030

Ventura County Hematology-Oncology Specialists, Oxnard

94010

Hopital Henri Mondor, Créteil

99208

Medical Oncology Associates, P.S., Spokane

00029

Helsingin yliopistollinen keskussairaala, Helsinki

Unknown

Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS, Bologna

Ospedale San Raffaele, Milan

KO-MED Centra Kliniczne, Biała Podlaska

Uniwersyteckie Centrum Kliniczne, Gdansk

BioResearch Group Sp. Z. o. o., Krakow

NASZ LEKARZ Osrodek Badan Klinicznych, Torun

ICO Badalona - Hospital Universitari Germans Trias i Pujol, Barcelona

ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona

Fundacion Jimenez Diaz, Madrid

Hospital Universitario Virgen del Rocio, Seville

Hospital Universitario Virgen Macarena, Seville

50-566

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego, Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Hutchmed

INDUSTRY